Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients With Cystic Fibrosis
Publication Date: November 18, 2017
Last Updated: March 14, 2022
Recommendations
Ivacaftor for gating mutations other than G551D or R117H
The committee recommends IVA for individuals aged 2–5 years with a diagnosis of CF and gating mutations other than G551D or R117H. For individuals under 2 years of age, the committee makes no recommendation. (, )
322286
The committee suggests IVA for individuals aged 6–11 years with a diagnosis of CF with PPFEV1 less than 40% and a gating mutation other than G551D or R117H. (C, VL)
322286
The committee suggests IVA treatment for individuals aged 6–11 years with a diagnosis of CF with PPFEV1 40%–90% and a gating mutation other than G551D or R117H. (C, L)
322286
The committee suggests IVA be used for individuals aged 6–11 years with a diagnosis of CF with PPFEV1 greater than 90% and a gating mutation other than G551D or R117H. (C, L)
322286
The committee suggests IVA for individuals aged 12–17 years with a diagnosis of CF with PPFEV1 40%–90% and a gating mutation other than G551D or R117H. (C, L)
322286
The committee suggests IVA for individuals aged 12–17 years with a diagnosis of CF with PPFEV1 greater than 90% and a gating mutation other than G551D or R117H. (C, M)
322286
The committee suggests IVA for individuals aged 18 years or older with a diagnosis of CF with PPFEV1 less than 40% and a gating mutation other than G551D or R117H. (C, M)
322286
The committee suggests IVA for individuals with a diagnosis of CF aged 18 years or older with PPFEV1 40%–90% and a gating mutation G551D or R117H. (C, L)
322286
The committee suggests IVA for individuals aged 18 years or older with a diagnosis of CF with PPFEV1 greater than 90% and a gating mutation G551D or R117H. (C, M)
322286
The committee suggests IVA for individuals aged 12–17 years with a diagnosis of CF with PPFEV1 less than 40% and a gating mutation other than G551D or R117H. (C, M)
322286
Overview
Title
Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients With Cystic Fibrosis
Authoring Organization
Cystic Fibrosis Foundation